Back to search

Article

Anti-CD19 CAR T as a feasible and safe therapy for refractory/relapsed mixed phenotype acute leukemia (MPAL) patients

2022-01-20

Abstract excerpt

Mixed phenotype acute leukemia (MPAL) is a relatively rare and heterogeneous group of diseases, which account for 2-5% of leukemia. So far, no optimal treatment regimens have been established for MPAL patients. CD19 chimeric antigen receptor T (CAR T) therapy have shown remarkable efficacy in B-ALL patients. In this study, 5 MPAL patients received CD19 CAR T cell infusion and 3 out of 5 patients (60%) achieved com...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f2582eea-d67c-586a-85a4-8fcb2a6cbe6b
DOI
10.22541/au.164264604.42706238/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Anti-CD19 CAR T as a feasible and safe therapy for refractory/relapsed mixed phenotype acute leukemia (MPAL) patientsDOI 10.22541/au.164264604.42706238/v1
Select a neighboring publication to make it the new centre.